News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC

Jun 27, 2022 7:00am EDT

ADMA Biologics Announces Addition to the Russell 2000® Index

Jun 21, 2022 7:00am EDT

ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022 4:05pm EDT

ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

May 04, 2022 7:00am EDT

ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

Apr 01, 2022 7:00am EDT

ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

Mar 25, 2022 7:00am EDT

ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

Mar 24, 2022 4:05pm EDT

ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

Mar 21, 2022 7:00am EDT

ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

Mar 07, 2022 4:05pm EST

ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

Jan 19, 2022 7:00am EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...23
Next
About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

© Copyright 2022 ADMA Biologics, Inc.
Ramsey, NJ Offices 201-478-5552
Boca Raton, FL Offices 561-989-5800
info@admabio.com

Best places to work
Bio NJ

2020 Innovator Award

50 fastest companies
2019 Fast 500 Deloitte
Bio Florida

Named 2019 Company of the Year